RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+5.19%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.34B
AUM Growth
+$16.4M
Cap. Flow
-$1.65M
Cap. Flow %
-0.12%
Top 10 Hldgs %
51.3%
Holding
73
New
15
Increased
18
Reduced
22
Closed
16
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$54.1M
2
BSX icon
Boston Scientific
BSX
+$40.3M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$40.2M
4
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$34.8M
5
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$22.4M

Top Sells

Rank Stock Value
1
RAD
Rite Aid Corporation
RAD
+$49M
2
CMRX icon
Chimerix, Inc.
CMRX
+$40.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.8M
4
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$33.8M
5
INCY icon
Incyte
INCY
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Miscellaneous 9.9%
3 Communication Services 1.56%
4 Industrials 0.57%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
FOLD icon
1
DELISTED
Amicus Therapeutics
FOLD
$99.7M 7.46%
10,280,620
+1,947,690
+23% +$17.6M
2013 Q2
10 quarters
MDVN
2
DELISTED
MEDIVATION, INC.
MDVN
$77.3M 5.79%
1,599,393
-153,249
-9% -$6.61M
2015 Q3
1 quarter
PEN icon
3
Penumbra
PEN
$12.6B
$76.2M 5.7%
1,537,570
-25,017
-2% -$1.13M
2015 Q3
1 quarter
ARRY icon
4
DELISTED
Array Biopharma Inc
ARRY
$75.3M 5.64%
17,850,650
+100,140
+0.6% +$457K
2013 Q2
10 quarters
ITCI icon
5
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$65.8M 4.93%
1,223,717
-98,875
-7% -$4.99M
2014 Q1
7 quarters
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$62.9M 4.7%
1,795,936
+838,302
+88% +$54.1M
2013 Q2
10 quarters
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
$61.6M 4.61%
1,372,492
-17,681
-1% -$736K
2014 Q3
5 quarters
TEVA icon
8
Teva Pharmaceutical Industries Limited
TEVA
$48.2B
$61.6M 4.61%
938,139
-199,420
-18% -$12.3M
2015 Q1
3 quarters
SAGE icon
9
DELISTED
Sage Therapeutics
SAGE
$55.9M 4.18%
958,374
-184,490
-16% -$9.14M
2015 Q2
2 quarters
PTLA
10
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$49.3M 3.69%
958,155
+188,514
+24% +$9.14M
2015 Q2
2 quarters
WCG
11
DELISTED
Wellcare Health Plans, Inc.
WCG
$44M 3.29%
562,873
+48,600
+9% +$4.03M
2015 Q3
1 quarter
IRWD icon
12
Ironwood Pharmaceuticals
IRWD
$595M
$42.6M 3.18%
4,383,585
+4,155,783
+1,824% +$40.2M
2015 Q3
1 quarter
BSX icon
13
Boston Scientific
BSX
$61.5B
$41.5M 3.11%
+2,251,020
New +$40.3M
2015 Q4
0 quarters
PFE icon
14
CALL
Pfizer
PFE
$167B
$40.7M 3.04%
+1,328,462
New +$41.8M
2015 Q4
0 quarters
ATRA icon
15
Atara Biotherapeutics
ATRA
$95.4M
$40.5M 3.03%
61,398
+19,407
+46% +$14.7M
2014 Q4
4 quarters
INCY icon
16
Incyte
INCY
$22.6B
$38.8M 2.9%
357,912
-255,686
-42% -$28.5M
2015 Q2
2 quarters
DPLO
17
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$38.2M 2.86%
+1,115,902
New +$34.8M
2015 Q4
0 quarters
NVRO icon
18
DELISTED
NEVRO CORP.
NVRO
$28M 2.1%
415,198
+390,198
+1,561% +$20.9M
2015 Q3
1 quarter
NDRM
19
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$27.1M 2.03%
1,589,261
+126,562
+9% +$2.47M
2015 Q3
1 quarter
CNC icon
20
Centene
CNC
$34.2B
$26.9M 2.01%
816,000
-678,920
-45% -$20.1M
2015 Q3
1 quarter
INSM icon
21
Insmed
INSM
$21.3B
$25.3M 1.89%
1,391,813
+443,847
+47% +$7.82M
2014 Q3
5 quarters
UNH icon
22
UnitedHealth
UNH
$350B
$22M 1.65%
+187,034
New +$21.9M
2015 Q4
0 quarters
AGN
23
DELISTED
Allergan plc
AGN
$21.5M 1.61%
+68,758
New +$20.5M
2015 Q4
0 quarters
MODN icon
24
DELISTED
MODEL N, INC.
MODN
$20.8M 1.56%
1,868,159
+424,881
+29% +$4.53M
2013 Q4
8 quarters
ZLTQ
25
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$20.2M 1.51%
+709,426
New +$22.4M
2015 Q4
0 quarters
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2015 Portfolio in Review

As of Q4 2015, Redmile Group held 73 positions worth $1.34B, up 1.2% from $1.32B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Redmile Group's Q4 2015 filing shows 15 new, 18 increased, 22 reduced and 16 closed positions. Its largest new stake was Boston Scientific: 2,251,020 shares worth $41.5M. The largest sale was Rite Aid Corporation, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Communication Services.

  • Redmile Group's largest Q4 2015 buy was Boston Scientific: 2,251,020 shares worth $41.5M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q4 2015, an estimated $54.1M increase.
  • Redmile Group's biggest Q4 2015 reduction was Incyte, cutting an estimated $28.5M.
  • Redmile Group fully exited Rite Aid Corporation in Q4 2015, selling an estimated $49M.
  • Redmile Group's ten largest holdings make up 51% of its $1.34B portfolio in Q4 2015.
  • Redmile Group opened 15 new positions and closed 16 in Q4 2015.
  • Redmile Group's portfolio value rose 1.2% quarter-over-quarter to $1.34B.

Based on Redmile Group's 13F filing for Q4 2015, filed 16 Feb 2016.